My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

102.01 +2.13 (+2.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >

Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 19, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 18, 2023

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...

Via Benzinga

11 Analysts Have This to Say About Mirum Pharmaceuticals ↗

November 20, 2023

Via Benzinga

Analyst Ratings for Mirum Pharmaceuticals ↗

November 03, 2023

Via Benzinga

Earnings Outlook For Mirum Pharmaceuticals ↗

November 01, 2023

Via Benzinga

Analyst Ratings for Mirum Pharmaceuticals ↗

October 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

7 Small-Cap Stocks That Get the Nod from Wall Street ↗

October 11, 2023

Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts.

Via InvestorPlace

Why Shares of Travere Therapeutics Are Slumping Thursday ↗

September 21, 2023

A mixed trial could hurt a kidney drug's chances of full approval.

Via The Motley Fool

Analyst Ratings for Mirum Pharmaceuticals ↗

September 13, 2023

Via Benzinga

Where Mirum Pharmaceuticals Stands With Analysts ↗

August 21, 2023

Via Benzinga

The Latest Analyst Ratings for Mirum Pharmaceuticals ↗

June 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023 ↗

September 20, 2023

Via Benzinga

Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

September 06, 2023

Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.

Via Benzinga

Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know ↗

July 18, 2023

Via Benzinga

Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

July 18, 2023

B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02...

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

May 22, 2023

Via Benzinga

Mirum Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗

July 17, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...

Via Benzinga

Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗

June 03, 2023

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...

Via Talk Markets

Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 12, 2023

Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

April 06, 2023

Via Benzinga

Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 10, 2023

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

March 09, 2023

Via Benzinga

American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday ↗

April 12, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

January 10, 2023

Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...

Via Benzinga

Mirum Pharmaceuticals's Return On Capital Employed Insights ↗

December 14, 2022

Via Benzinga

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Earnings Preview: Mirum Pharmaceuticals ↗

March 07, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.